Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (917)	6/6/2001 10:55:38 AM
From: Pierre Borczuk	Read Replies (1) \| Respond to of 1475

Are there any published primary data for MEDI 507? Pierre

To: scaram(o)uche who wrote (917)	6/6/2001 5:30:17 PM
From: scaram(o)uche	Respond to of 1475

Wednesday June 6, 5:25 pm Eastern Time Press Release SOURCE: BioTransplant Incorporated BioTransplant Incorporated Announces Commitment for $17.8 Million Private Placement CHARLESTOWN, Mass., June 6 /PRNewswire/ -- BioTransplant Incorporated (Nasdaq: BTRN - news) today announced that it has commitments from selected institutional and accredited investors to consummate a private placement of approximately 2.83 million shares of newly issued common stock, at a purchase price of $6.30 per share, for aggregate gross proceeds of approximately $17.8 million. Pending consummation of the private placement, the Company intends to use the proceeds from the sale of its common stock to advance its immune modulation therapy programs encompassing the clinical development of its AlloMune(TM) family of product candidates, the expansion of development and commercialization of its Eligix Cell Separation Systems and to provide it with working capital for other general corporate purposes. The shares of common stock to be sold in this private placement have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States, except pursuant to an effective registration statement or an applicable exemption from registration requirements. Pending consummation of the private placement, the Company expects to promptly file a resale registration statement on Form S-3 for purposes of registering the resale of the shares of common stock. This press release does not constitute an offer to sell or the solicitation of an offer to buy the common stock. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act. Contacts: BioTransplant Incorporated Noonan/Russo Communications, Inc. Richard Capasso Prateek Patnaik (Media), x273 Vice President, Finance & Treasurer Sharon Weinstein (Investor), x334 617-241-5200 212-696-4455 biotransplant.com noonanrusso.com SOURCE: BioTransplant Incorporated